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Summary at a Glance 
Hospitalized adults with community acquired pneumonia have low prevalence of 
Enterobacteriacea (6%) and multidrug-resistant Enterobacteriacea (1.2%), respectively. 
Specific risk factors, such as prior extended-spectrum beta-lactamase infection and being 
underweight, should raise the clinical suspicion for Enterobacteriace and multidrug-
resistant Enterobacteriace in patients hospitalized with CAP. 
 
ABBREVIATION LIST 
CAP: Community-acquired pneumonia 
EB: Enterobacteriaceae 
MDR-EB: Multidrug-resistant Enterobacteriaceae 
COPD: Chronic obstructive pulmonary disease  
VAP: Ventilator associated pneumonia 
HAP: Hospital-acquired pneumonia 
BAL: Bronchoalveolar lavage  
CLSI: Clinical Laboratory Standards Institute 
 
 









This article is protected by copyright. All rights reserved.
 6 
Author contribution roles using the CRediT Taxonomy  
Please complete this Table on behalf of and with approval of all authors 
-Note that not all categories are relevant to each type of research  Only select those contribution 
roles that are relevant to your study. 
-This information will be translated into an ‘Author contribution statement’ by the typesetters and 
included at the end of your publication  The corresponding author is responsible for checking the 
‘Author contribution statement’ against the completed table below in the final version of the 
manuscript.  
- DO NOT FORGET:  If not done yet, you will ALSO be required to complete the same Author 
contribution information for all authors in ScholarOne at Step 4 of the First Look finalization. 
 
Role  Degree Author initials  (reflecting the full author name on the manuscript) 
1 -Conceptualization 
    Lead MIR, SA, DV 
Equal PF, LFR 
Supporting NJS, PJM, RGW, AR, OS, FS, IML, FM, MJ, MS 
2 - Data curation 
    Lead MIR, DV, SA,NJS 
Equal LFR  
Supporting PF, PJM, RGW, AR, OS, FS, IML, FM, MJ, MS 
3 -Formal analysis 
    Lead MIR, DV, SA,NJS 
Equal LFR 
Supporting PF, PJM, RGW, AR, OS, FS, IML, FM, MJ, MS 
4 - Funding acquisition 
    Lead NA 
Equal NA 
Supporting NA 
5 - Investigation 
    Lead MIR, DV, SA, NJS, LFR, PF, PJM, RGW, AR, OS, FS, IML, FM, MJ, MS 
Equal GLIMP investigators 
Supporting NA 
6 - Methodology 
    Lead MIR, SA, DV 
Equal PF, LFR 
Supporting NJS, PJM, RGW, AR, OS, FS, IML, FM, MJ, MS 
This article is protected by copyright. All rights reserved.
 7 
7 - Project 
administration 
    Lead MIR, SA, DV 
Equal PF, LFR 
Supporting NJS, PJM, RGW, AR, OS, FS, IML, FM, MJ, MS 
8 - Resources 
    Lead NA 
Equal NA 
Supporting NA 
9 - Software 
    Lead MIR, SA, DV, LFR 
Equal NA 
Supporting NA 
10 - Supervision 
    Lead MIR, SA 
Equal NA 
Supporting PF, LFR, NJS, PJM, RGW, AR, OS, FS, IML, FM, MJ, MS 
11 - Validation 
    Lead MIR, SA, DV 
Equal NA 
Supporting PF, LFR, NJS, PJM, RGW, AR, OS, FS, IML, FM, MJ, MS 
12 - Visualization 
    Lead MIR, SA, DV 
Equal NA 
Supporting PF, LFR, NJS, PJM, RGW, AR, OS, FS, IML, FM, MJ, MS 
13 - Writing – original 
draft  
    Lead MIR, SA, DV 
Equal NA 
Supporting PF, LFR, NJS, PJM, RGW, AR, OS, FS, IML, FM, MJ, MS 
14 - Writing – review & 
editing  
    Lead MIR, SA, DV 
Equal NA 
Supporting PF, LFR, NJS, PJM, RGW, AR, OS, FS, IML, FM, MJ, MS 
 
  
This article is protected by copyright. All rights reserved.
 8 
ABSTRACT  
Background and objective: Enterobacteriaceae (EB) spp. family is known to include 
potentially multidrug-resistant microorganisms, and remains as an important cause of 
community-acquired pneumonia (CAP) associated with high mortality. The aim of this 
study was to determine the prevalence and specific risk factors associated with EB and 
multidrug-resistant EB in a cohort of hospitalized adults with CAP. 
Methods: We performed a multinational, point-prevalence study of adult patients 
hospitalized with CAP. Multidrug-resistant EB was defined when ≥3 antimicrobial 
classes were identified as non-susceptible. Risk factors assessment was also performed 
for patients with EB and multidrug-resistant EB infection. 
Results: Of 3,193 patients enrolled with CAP, 197 (6%) had a positive culture with EB. 
Fifty one percent (n=100) of EB were resistant to at least one antibiotic and 19% (n=38) 
had multidrug-resistant EB. The most commonly EB identified were Klebsiella 
pneumoniae (n=111, 56%) and Escherichia coli (n=56, 28%). The risk factors that were 
independently associated with EB -CAP were male gender, severe CAP, underweight 
(BMI<18.5), and prior extended-spectrum beta-lactamase infection. Additionally, prior 
extended-spectrum beta-lactamase infection, being underweight, cardiovascular diseases 
and hospitalization in the last 12 months were independently associated with multidrug-
resistant EB CAP.  
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Conclusion: This study of adults hospitalized with CAP found a prevalence of EB of 6% 
and multidrug-resistant EB of 1.2%, respectively. The presence of specific risk factors, 
such as prior extended-spectrum beta-lactamase infection and being underweight, should 
raise the clinical suspicion for EB and multidrug-resistant EB in patients hospitalized 
with CAP. 
 
Key words: Community-acquired pneumonia, Enterobacteriaceae, multidrug-resistance, 
prevalence, risk factors. 
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INTRODUCTION 
Community-acquired pneumonia (CAP) is a leading infectious cause of death 
worldwide, and is a costly illness due to its mortality and long-term morbidity.1-3 Current 
Infectious Diseases Society of America (IDSA)/American Thoracic Society (ATS) 
guidelines recommend the use of a respiratory fluoroquinolone as monotherapy or a β-
lactam antibiotic (usually third-generation cephalosporin) plus a macrolide as initial 
therapy for outpatient and non-intensive care unit (ICU) inpatient treatment of CAP.4,5 
However, after these guidelines were published 10 years ago, an alarming increase in 
antimicrobial resistance to these first-line antibiotics has emerged in the common 
bacterial pathogens known to cause CAP.6,7 
Streptococcus pneumoniae remains as the most common bacterial pathogen 
identified in patients with CAP.8,9 However, several pathogens thought to be confined to 
hospital settings have been isolated more frequently in patients with CAP.9,10 Of these 
pathogens, gram-negative rods (GNR), such as Pseudomonas aeruginosa, Acinetobacter 
spp., and the Enterobacteriaceae spp. family, have become important causes of lower 
respiratory tract infections.11,12 More importantly, these gram-negative bacteria are often 
drug-resistant microorganisms associated with high mortality and have been linked to 
infections in chronically-ill, healthcare-exposed and immunocompromised patients.12,13  
Few studies have assessed the prevalence of the Enterobacteriaceae spp. (EB) 
family (Klebsiella pneumoniae, Escherichia coli, Enterobacter spp., Proteus spp., 
This article is protected by copyright. All rights reserved.
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Serratia spp.) in CAP patients.14 Thus, limited data are available regarding the risk 
factors associated with enteric GNRs, especially resistant Enterobacteriaceae spp. 
pathogens. The aim of the present study was to determine the prevalence and specific risk 
factors associated with EB and multidrug-resistant (MDR) EB infection in CAP patients 




Study design and setting 
This was a multinational (54 countries), multicenter (222 participating hospitals), 
point-prevalence study of adult patients (>18 years of age) hospitalized with CAP. The 
University of Texas Health San Antonio was the coordinating center and received 
approval by the Institutional Review Board (IRB# HSC20150184E) to administer the 
study. All centers that participated in the study complied with local, regional, and/or 
national research regulations. An international research oversight committee was 
established in October 2014 to oversee all aspects of developing and executing the study 
protocol (SA, LFR, PF and MIR).15  
Electronic invitations were sent to members of different professional societies 
worldwide from internal and emergency medicine, infectious diseases, critical care and 
pulmonary medicine. Invitations were also sent to multiple authors of publications of 
This article is protected by copyright. All rights reserved.
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MDR pathogens in CAP. Site investigators voluntarily agreed to participate, and no 
funding was provided. Study participants were diagnosed and treated per local standards 
of care, including microbiological assessment and treatment decisions, without any 
feedback from the study oversight committee or predetermined protocols. We enrolled 
participants on four days randomly selected by each site investigator during the months 
of March, April, May, and June 2015; to assure patient de-identification.15 
 
Inclusion criteria 
We included hospitalized adult patients ≥18 years of age with diagnosis of CAP 
defined by IDSA/ATS CAP guidelines.4  Briefly, CAP was confirmed by the presence of 
pulmonary infiltrates <48 hours of admission by chest imaging (chest radiography, lung 
ultrasound or computed tomography) and the presence of  ≥1 of the following signs and 
symptoms: 1) a new or augmentation of the cough reflex with or without sputum 
production and/or purulent respiratory secretions; 2) fever (documented by rectal or oral 
temperature ≥37.8 °C) or hypothermia (<36oC by rectal or oral temperature); 3) evidence 
of systemic inflammation, such as leukocytosis (>10,000/cm3), leukopenia (< 4,000/cm3), 
bandemia (>10%), increased C-reactive protein or procalcitonin levels.  
 
Exclusion criteria 
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We excluded patients with nosocomial pneumonia, such as hospital-acquired 
and/or ventilator-associated pneumonia, as defined by current clinical guidelines.16 
Patients for whom site investigators did not report blood, sputum, or lower respiratory 
tract cultures obtained within 24 hours of hospital admission were also excluded due to 
our inability to identify the etiological pathogen.15 
 
Data collection 
We used the validated data capture tool (REDCap™, Research Electronic Data 
Capture) hosted at UT Health San Antonio server to collect and manage study data.17 
After study enrolment, we allowed participating sites 7 days to complete electronic data 
entry and confirm microbiological results. All data were anonymized before being 
transmitted to the coordinating center. 
 
Microbiological analysis 
Microbiological testing and processing were conducted according to local 
standard protocols for sputum, urine, and blood during the first 24 hours of 
hospitalization. Additionally, data on pleural fluid, tracheobronchial aspirate, and 
bronchoalveolar lavage fluid, were collected if they were available. Each laboratory 
complied with local quality control protocols or those of the Clinical and Laboratory 
Standards Institute.18,19  
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Gram-negative bacilli pathogens belonging to the family of Enterobacteriaceae 
spp. included Klebsiella pneumoniae, Escherichia coli, Enterobacter spp., Proteus spp., 
and Serratia spp. Antibiotic resistance was assessed by testing resistance against major 
classes of antimicrobial agents (e.g., beta-lactams, carbapenems, aminoglycosides, 




Multidrug-resistant Enterobacteriaceae spp. (MDR-EB) was defined as resistance 
to ≥3 antimicrobial classes known to be active against these pathogens,20 when obtained 
from blood, or respiratory sources, such as: sputum, bronchoalveolar lavage, or pleural 
fluid.   
Chronic lung diseases were defined as the group of conditions that include 
asthma, bronchiectasis, COPD, chronic aspiration, tracheostomy present at the time of 
admission and long term oxygen therapy. 
Severe CAP was defined as patients with a CAP diagnoses that required 
admission to the intensive care unit, and/or invasive or non-invasive mechanical 
ventilation, or required vasopressors/inotropes in the first 24 hours of hospital admission. 
All study definitions were provided to local investigators prior to the starting data 
collection. 




The EB and MDR-EB prevalence were calculated using EB and MDR-EB 
isolates as the numerator, and total number of enrolled patients as the denominator, 
respectively (Figure 1). Using the Chi-squared test we compared categorical variables, 
expressed as counts (percentages), between the study groups. We performed regressions 
analyses to compare prevalence among the participating sites, representing different 
continents and countries. We assessed in a logistic regression analysis the relationship 
between the two dependent variables (EB and MDR-EB CAP) with the variables that 
showed a p value <0.05 in the bivariate analysis. Odds ratios (OR) with 95% confidence 
interval (CI) were used to present regression analysis results. Statistical significance of 
the results was defined as p-value <0.05. Statistical analyses were performed with IBM 
SPSS, Statistics for Mac, version 22.0, Armonk, NY: IBM Corp.  
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RESULTS 
A total of 3,702 patients were enrolled in the study and 509 of them were 
excluded due to the lack of microbiological information. 3,193 patients with signs and 
symptoms consistent with CAP in whom at least one microbiological culture was 
obtained within the first 24 hours of hospital admission were enrolled in the study. In 
1,173 patients, at least one pathogen was identified in the culture samples, and they were 
considered the culture-positive cohort (Figure 1). 
 
Enterobacteriaceae prevalence and geographical distribution 
EB were identified in 197 (6%) of 3,193 patients enrolled in the study (Figure 2, 
Panel A, Table S1 in the Supplementary Information). Among the 197 patients with EB 
pneumonia, 190 were monomicrobial EB and 7 were polymicrobial (combinations of two 
EBs) (Figure 2, panel C). Of the EB identified, the most frequently isolated pathogens 
were K. pneumoniae (n=111; 56%), E. coli (n=56; 28%), Enterobacter spp. (n=25; 13%), 
Proteus spp. (n=8; 4%), and Serratia spp. (n=4; 2%) (Figure 3, panel A). The prevalence 
of EB among the 6 continents was highest in Africa (n=23, 18%) (Table 1). The countries 
that showed the highest prevalence of EB above 10% were: Colombia, Nigeria, Moldova, 
Croatia, Egypt and Germany compared to other participating countries (Table S1 in the 
Supplementary Information). 
 






From the 197 EB identified, 97 (49%) were sensitive to the antibiotics tested, 62 
(31%) were resistant to one or two antimicrobials and 38 (19%) were classified as MDR-
EB (Figure 3, panel B). EB showed resistance to fluoroquinolones (n=61; 31%), 
piperacillin-tazobactam (n=60; 30%), cephalosporins (n=56; 28%), aminoglycosides 
(n=27; 14%) and carbapenems (n=16; 8%) (Figure 3, panel E). 
 
Multidrug-resistant Enterobacteriaceae prevalence and geographical distribution 
Among the isolated EB, 19% (n=38) were confirmed to be MDR-EB with a 
prevalence rate of 1.2% (Figure 2, panel D).  In addition, the continent with the highest 
prevalence of MDR-EB was Africa (n=8, 6.3%) (Table 1). The countries with the highest 
prevalence of MDR-EB above 5% were: Nigeria (7.7.%), Colombia (7.4%) and Moldova 
(6.5%) (Table S1 in the Supplementary Information). 
 
Risk factors for Enterobacteriaceae  
In the univariate analysis, several variables were associated with EB CAP (Table 
1; Table S2 in the Supplementary Information). In the multivariate logistic regression 
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analysis, we found that the risk factors that were independently associated with EB-CAP 
were prior extended-spectrum beta-lactamase (ESBL) infection (OR: 4.04; 95%CI: 2.04-
8.01, p<0.01), being underweight (OR: 2.25, 95%CI: 1.31-3.86, p<0.01), severe CAP 
(OR: 2.41, 95%CI: 1.79-3.25, p<0.01) and male gender (OR: 1.48, 95%CI: 1.08-2.02, 
p=0.01) (Table 2). In culture-positive CAP patients, risk factors independently associated 
were prior ESBL infection (OR: 3.71, 95%CI: 1.65-8.35, p<0.01), being underweight 
(OR: 2.02, 95%CI: 1.13-3.63, p=0.02), and severe CAP (OR: 1.78, 95%CI: 1.30-2.45, 
p<0.01)(Table 2).  
 
Risk factors for multidrug-resistant Enterobacteriaceae 
Prior ESBL infection (OR: 8.50, 95%CI: 3.12-23.16, p<0.01), being underweight 
(OR: 2.76, 95%CI: 1.07-7.12, p=0.04), cardiovascular diseases (OR 0.44; 95%CI: 0.22-
0.90, p=0.02) and hospitalization in the last 12 months (OR: 2.67, 95%CI: 1.18-6.03, 
p=0.02) were the risk factors independently associated with MDR-EB CAP (Table 2). 
The risk factors independently associated with MDR-EB enrolled in the culture-positive 
cohort were prior ESBL infection (OR: 5.60, 95%CI: 1.86-16.80, p<0.01), cardiovascular 
diseases (OR 0.43; 95%CI: 0.21-0.91, p=0.03), and hospitalization in the last 12 months 
(OR: 2.36, 95%CI: 1.17-4.78, p=0.02) (Table 2). 
 
  




This multinational study showed that patients with community-acquired 
pneumonia have a 6% prevalence of Enterobacteriaceae as an etiological pathogen. The 
prevalence among the 6 continents enrolled were variable, ranging from 4-18% for EB 
CAP and 0.6-6.3% for MDR-EB CAP, with the highest prevalence rates found in Africa. 
Prior ESBL infection and being underweight were independently associated with both EB 
and MDR-EB in patients with CAP.  
The overall prevalence rates of EB and MDR-EB CAP identified in this study 
were higher (6% and 1%, respectively) compared to the 1-3% prevalence rate of EB CAP 
(excluding Pseudomonas aeruginosa and Acinetobacter spp.) reported in three 
observational studies from Spain,21-23 and in one from Germany.24 Moreover, in patients 
with culture positive results, the denominator drives a higher prevalence of EB and 
MDR-EB in CAP patients, resulting in 17% and 3%, in contrast to ~2-6% (only for EB-
CAP) reported in the previously mentioned studies.21-24 It is important to mention that 
participation for this study was voluntary and it could have certainly account for some 
countries and continents contributing to a higher number of patients enrolled. We 
hypothesized that regional variability between patients’ characteristics, healthcare 
systems in developed and developing countries, risk factors, and antibiotic resistance 
patterns, might have played a role in the differences observed. Therefore, these data 
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suggest that identifying the common pathogens that cause CAP is necessary to appreciate 
the frequency of these pathogens at any given time, which can guide antimicrobial 
treatment strategies. 
The EB pathogens isolated in our study are consistent with previous reports that 
found K. pneumoniae and E. coli to be the most commonly isolated EB in CAP.21,24,25 
Enterobacter spp., Proteus spp., and Serratia spp. were less commonly identified in 
patients hospitalized with CAP among the 54 participating countries in our study. Current 
guideline-recommended empiric antibiotic therapy that include a third-generation 
cephalosporin and a macrolide or monotherapy with a respiratory fluoroquinolone4 for 
patients with CAP would not cover 30% of isolated EB due to in-vitro resistance at 
presentation. More than half of the EB isolated pathogens showed resistance to ≥1 of the 
tested antibiotics and one third of the EB demonstrated to be MDR. These numbers 
should raise awareness of the emerging antimicrobial resistance to bacterial pathogens, 
particularly in CAP patients.  
A major finding of the present study is that prior ESBL infection and being 
underweight were both independent risk factors for EB and MDR-EB CAP. Few studies 
have evaluated the risk factors associated with EB CAP, and these studies often included 
P. aeruginosa and Acinetobacter spp., as EB.21,22,24,26 Underweight has been associated 
with the development of CAP, but not specifically with EB or MDR-EB. A detailed 
systematic review that evaluated the risk factors associated with CAP found that poor 
This article is protected by copyright. All rights reserved.
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nutritional status that in different studies is related to hypoalbuminemia, 
hypoproteinemia, malnourishment, malnutrition, or a low nutritional score was a strong 
predictor of CAP 27. However, in contrast Cilloniz C. et al. presented a comprehensive 
review of the topic and did not mentioned low body mass index or underweight 
associated with any of potential MDR pathogens including EB 28. Despite this, prior 
investigations showed that CAP due to EB tends to be associated with exposure to the 
healthcare system, such as previous antibiotic use, current use of corticosteroids, prior 
hospital admission, probable aspiration, severe CAP, and comorbidities of the 
cardiovascular, cerebrovascular, and pulmonary systems.21,22,26 Our assessment of 
individual risk factors identified that the prior evidence of P. aeruginosa infection and at 
least one of three lung diseases (i.e. tracheostomy present on admission, bronchiectasis 
and very severe COPD [Forced expiratory volume in one second less than 30%]) were 
independently associated with P. aeruginosa CAP.29 Therefore, our data suggest that 
there is no significant overlap among the risk factors associated with P. aeruginosa CAP 
and the ones associated with EB CAP, respectively. The EB risk factors suggested in our 
study may assist clinicians to further individualize the selection of antibiotics by limiting 
the unnecessary coverage for P. aeruginosa in certain patients with CAP.  
This is one of the first international studies involving more than 50 countries 
around the world that systematically evaluated the prevalence and risk factors for EB and 
MDR-EB in CAP patients, and should be considered one of its main strengths.  This 
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point-prevalence study carries some limitations inherent to the study design, such as the 
inability to follow patients over time and track the outcomes beyond the period of 
observation. In addition, due to the nature of the study, we were not allowed to report 
identifiable data and therefore, it was not possible to return to the individual patient 
medical records to confirm that each variable was entered appropriately. We relied on the 
honesty and the accountability of each one of the site investigators to follow the ethical 
rules defined by the individual study centers. Additionally, we attempted to standardize 
the methodology through the training videos, data abstraction form and data dictionary, 
as well as microbiological standard testing according to international standards. This 
study does not attempt to generalize other epidemiological reports or outbreaks in centers 
not participating in this study and from sources other than CAP. In addition, MDR EB 
could represent an important source of hospital-acquired infections not evaluated in our 
study. Microbiologic genetic testing was not performed, as it is not available in resource-
limited countries included in this study. Finally, there is a possibility that a small 
proportion of patients (n=13 [6.6.%]) with prior ESBL infection may represent a relapse 
or recurrence infection with the same microorganism. However, the data obtained in this 
point-prevalence study did not include the source of prior ESBL infection, the resolution 
of the prior disease and/or the time from prior infection to current EB CAP event. 
In conclusion, the prevalence of EB- and MDR-EB as etiological pathogens of 
CAP is 6% worldwide. Despite the alarming rise of MDR-EB, most of the guideline-
This article is protected by copyright. All rights reserved.
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recommended empiric antibiotic regimens would still cover the pathogens most 
frequently causing CAP. Selection of empiric antibiotic therapy for patients with CAP 
should consider the prevalence of antibiotic-resistant pathogens in the community and 
identify certain risk factors that may change the probability of MDR-EB CAP. Future 
studies should explore how these variables influence the use of empiric antibiotics in 
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FIGURE LEGENDS 
Figure 1. Study flow diagram 
 
Figure 2: Panel A: Prevalence of Enterobacteriaceae (EB) among patients with CAP 
(microbiologically-tested cohort). Panel B: Prevalence of EB in culture-positive CAP. 
Panel C: Percentage of monomicrobial and polymicrobial EB CAP. Panel D: Prevalence 
of MDR-EB among in the microbiologically-tested cohort. Panel E: Prevalence of MDR-
EB in culture-positive CAP. Panel F: Prevalence of resistant and multidrug-resistant EB.  
 
Figure 3: Panel A: Types of Enterobacteriaceae (EB) among total EB isolated (n=197).  
Panel B: Antibiotic susceptibility among isolated EB. Panel C: Percentage of resistance 
and multidrug-resistance among EB that showed to be resistant to at least one antibiotic 
(n=100). Panel D: Number of bacteria by type that showed resistance to each one of the 













Table 1. Characteristics of all patients with community-acquired pneumonia (CAP) 
(n=3,193) due to Enterobacteriaceae (EB) and multidrug-resistant (MDR)-EB in 


































Age, median (IQR) 
years 68 (54-80) 
66 (54-
78) 0.68 68 (54-80) 
66 (47-
76) 0.17 
Male gender, n (%) 1,744 (58.2) 133 (67.5) 0.01 
1,855 
(58.8) 22 (57.9) 0.91 
Underweight, n (%) 132 (4.4) 18 (9.1) <0.01 144 (7.1) 6 (20.7) 0.04 
Alcoholism 250 (8.3) 17 (8.6) 0.89 266 (8.4) 1 (2.6) 0.20 
Current/former 
smoker, n (%) 
1,043 
(34.8) 71 (36) 0.73 
1,099 
(34.8) 15 (39.5) 0.55 
Bedridden, n (%) 322 (10.7) 31(15.7) 0.03 345 (10.9) 8 (21.1) 0.04 
Nursing home 
resident, n (%) 238 (7.9) 20 (10.2) 0.27 252 (8.0) 6 (15.8) 0.08 
Chronic medical comorbidities 
Chronic lung diseases 
Active lung cancer, 
n (%) 86 (2.9) 6 (3.0) 0.89 91 (2.9) 1 (2.6) 0.92 
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Asthma, n (%) 225 (7.5) 9 (4.6) 0.13 234 (7.4) 0 (0.0) 0.81 
Bronchiectasis, n 
(%) 153 (5.1) 15 (7.6) 0.13 161 (5.1) 7 (18.4) <0.01 
Chronic aspiration, 
n (%) 191 (6.4) 27 (13.7) <0.01 210 (6.7) 8 (21.1) <0.01 
COPD, n (%) 775 (25.9) 59 (29.9) 0.21 823 (26.1) 11 (28.9) 0.69 
FEV1 ≤30%, n (%) 82 (2.7) 8 (4.1) 0.28 88 (2.8) 2 (5.3) 0.36 
Oxygen therapy at 
home, n (%) 187 (6.2) 21 (10.7) 0.02 202 (6.4) 6 (15.8) 0.02 
Tracheostomy, n 
(%) 38 (1.3) 12 (6.1) <0.01 47 (1.5) 3 (7.9) <0.01 
Cardiovascular diseases 
Coronary artery 
disease, n (%) 487 (16.3) 39 (19.8) 0.19 524 (16.6) 2 (5.3) 0.06 




) 74 (37.6) 0.03 
1,435 
(45.5) 9 (23.7) <0.01 
Other comorbid conditions 
Diabetes mellitus, n 
(%) 637 (21.3) 44 (22.3) 0.72 674 (21.4) 7 (18.4) 0.66 
Enteral tube 
feeding, n (%) 39 (1.3) 9 (4.6) <0.01 44 (1.4) 4 (10.5) <0.01 
Liver disease, n 
(%) 121 (4) 8 (4.1) 0.99 125 (4) 4 (10.5) 0.04 
Cirrhosis, n (%) 59 (2) 5(2.5) 0.58 62 (2) 2 (5.3) 0.15 
Chronic renal 
failure, n (%) 329 (11) 20 (10.2) 0.72 344 (10.9) 5 (13.2) 0.66 
Stroke, n (%) 231 (7.7) 19 (9.6) 0.33 245 (7.8) 5 (13.2) 0.22 
Active solid tumor, 
n (%) 227 (7.6) 18 (9.1) 0.43 243 (7.7) 2 (5.3) 0.57 
Immunocompromis




infection, n (%) 
41 (1.4) 13 (6.6) <0.01 48 (1.5) 6 (15.8) <0.01 
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Prior healthcare exposure 
Hospitalization 
during the last 12 
months, n (%) 
950 (31.7) 76 (38.6) 0.04 1,004 (31.8) 22 (57.9) <0.01 
IV antibiotics during 
the last 12 months, n 
(%) 
747 (24.9) 65 (33.0) 0.01 796 (25.2) 16 (42.1) 0.02 
Severity of illness 
Severe CAP, n (%) 866 (28.9) 99 (50.3) <0.01 950 (30.1) 15 (39.5) 0.21 
Continents 
Europe (n=1.941) 1837 (94.6) 104 (5.4) 0.02 
1923 
(99.1) 18 (0.9) 0.1 
North America 
(n=484) 463 (95.7) 21 (4.3) 0.08 481 (99.4) 3 (0.6) 0.26 
Asia (n=405) 376 (92.8) 29 (7.2) 0.38 400 (98.8) 5 (1.2) 0.81 
South America 
(n=203) 186 (91.6) 17 (8.4) 0.18 200 (98.5) 3 (1.5) 0.73 
Africa (n=128) 105 (82.0) 23 (18) <0.01 120 (93.8) 8 (6.3) <0.01 
Oceania (n=32) 29 (90.6) 3 (9.4) 0.45 31 (96.9) 1 (3.1) 0.32 
CAP = community-acquired pneumonia; EB = Enterobacteriaceae spp.; NON-EB = Non-
Enterobacteriaceae; COPD = Chronic obstructive pulmonary disease; FEV1 = Forced 
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Risk factors 









OR (95% CI) p-value OR (95% CI) 
p-
value OR (95% CI) p-value OR (95% CI) 
p-
value 
Sex (male) 1.48 (1.08-2.02) 0.01   1.37 (0.99-1.92) 0.06   
Underweight 2.25 (1.31-3.86) <0.01 2.76 (1.07-7.12) 0.04 2.02 (1.13-3.63) 0.02 2.29 (0.85-6.12) 0.10 
Chronic lung diseases* 1.20 (0.88-1.63) 0.24 1.36 (0.68-2.73) 0.38 1.19 (0.86-1.64) 0.30 1.27 (0.62-2.58) 0.51 
Enteral tube feeding 1.78 (0.78-4.08) 0.17 3.50 (1.02-12.02) 0.05 1.76 (0.68-4.58) 0.25 3.17 (0.86-11.76) 0.08 
Bedridden status 1.11 (0.72-1.72) 0.62 1.32 (0.56-3.10) 0.53 1.19 (0.74-1.90) 0.48   
Prior ESBL infection 4.04 (2.04-8.01) <0.01 8.50 (3.12-23.16) <0.01 3.71 (1.65-8.35) <0.01 5.60 (1.86-16.80) <0.01 
Hospitalization during 
last 12 months 1.13 (0.77-1.68) 0.53 2.67 (1.18-6.03) 0.02   2.36 (1.17-4.78) 0.02 
IV antibiotics during last 
12 months 1.07 (0.71-1.62) 0.76 0.75 (0.32-1.77) 0.52     
Severe CAP 2.41 (1.79-3.25) <0.01   1.78 (1.30-2.45) <0.01   
Chronic liver disease   2.67 (1.01-7.11) 0.05     
Cardiovascular diseases** 0.84 (0.62-1.13) 0.25 0.44 (0.22-0.90) 0.02 1.00 (0.73-1.39) 0.98 0.43 (0.21-0.91) 0.03 
Chronic renal failure       1.75 (0.62-4.91) 0.29 
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Table 2. Multivariate regression analysis among CAP and culture-positive CAP patients demonstrating the risk factors independently 
associated with Enterobacteriaceae (EB) and multidrug-resistant (MDR) EB community-acquired pneumonia. 
 
CAP = Community-acquired pneumonia; EB = Enterobacteriaceae spp.; MDR = Multidrug-resistant; ESBL = Extended-spectrum beta-lactamase; 
IV= intravenous 
*Chronic lung diseases include asthma, bronchiectasis, COPD, chronic aspiration, tracheostomy present at the time of admission and long term 
oxygen therapy. ** Cardiovascular diseases included coronary artery disease, hypertension and heart failure. 
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